BRPI0515516B1 - Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition. - Google Patents

Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition. Download PDF

Info

Publication number
BRPI0515516B1
BRPI0515516B1 BRPI0515516-9A BRPI0515516A BRPI0515516B1 BR PI0515516 B1 BRPI0515516 B1 BR PI0515516B1 BR PI0515516 A BRPI0515516 A BR PI0515516A BR PI0515516 B1 BRPI0515516 B1 BR PI0515516B1
Authority
BR
Brazil
Prior art keywords
protein
immunogenic composition
immunogenic
group
staphylococcal
Prior art date
Application number
BRPI0515516-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Castado Cindy
Pierre Fernand Lecrenier Nicolas
Poolman Jan
Anne Neyt Cecile
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515516(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0421081A external-priority patent/GB0421081D0/en
Priority claimed from GB0421078A external-priority patent/GB0421078D0/en
Priority claimed from GB0421082A external-priority patent/GB0421082D0/en
Priority claimed from GB0421079A external-priority patent/GB0421079D0/en
Priority claimed from GB0503143A external-priority patent/GB0503143D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Priority to BR122016029840-0A priority Critical patent/BR122016029840B1/pt
Publication of BRPI0515516A publication Critical patent/BRPI0515516A/pt
Publication of BRPI0515516B1 publication Critical patent/BRPI0515516B1/pt
Publication of BRPI0515516B8 publication Critical patent/BRPI0515516B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0515516-9A 2004-09-22 2005-09-20 Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition. BRPI0515516B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0421081.1 2004-09-22
GB0421079.5 2004-09-22
GB0421081A GB0421081D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421078A GB0421078D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421082.9 2004-09-22
GB0421082A GB0421082D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421079A GB0421079D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421078.7 2004-09-22
GB0503143.0 2005-02-15
GB0503143A GB0503143D0 (en) 2005-02-15 2005-02-15 Immunogenic composition
PCT/EP2005/010184 WO2006032472A2 (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei

Publications (3)

Publication Number Publication Date
BRPI0515516A BRPI0515516A (pt) 2008-07-29
BRPI0515516B1 true BRPI0515516B1 (pt) 2017-08-08
BRPI0515516B8 BRPI0515516B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25

Family

ID=36000843

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0515520-7A BRPI0515520A (pt) 2004-09-22 2005-09-20 composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
BRPI0515516-9A BRPI0515516B1 (pt) 2004-09-22 2005-09-20 Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0515520-7A BRPI0515520A (pt) 2004-09-22 2005-09-20 composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica

Country Status (17)

Country Link
US (6) US20080095777A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (9) EP2298340B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP2008513406A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (4) KR101359930B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN101128215B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2005287505A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BRPI0515520A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (4) CA2983954C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (4) ES2730275T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (4) IL181825A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (2) MA28994B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX2007003400A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO20071610L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (4) NZ582441A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2402347C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (3) WO2006032500A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200702224B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
RU2402347C2 (ru) * 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
CA2583121A1 (en) 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
JP2008517900A (ja) * 2004-10-25 2008-05-29 ザ ユニバーシティ オブ ウェスタン オンタリオ スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
UA95238C2 (uk) * 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
EP2368569A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
SG170090A1 (en) * 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
ES2396453T3 (es) * 2006-04-24 2013-02-21 Sigma Alimentos, S.A. De C.V. Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
WO2007145689A1 (en) * 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP2374466B1 (en) * 2007-05-04 2013-08-28 Krönke, Martin Protective staphylococcus aureus vaccine based on cell wall-associated proteins
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
WO2009023164A2 (en) * 2007-08-10 2009-02-19 President And Fellows Of Harvard College Induction of mucosal immunity
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2697538C (en) * 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2268618B1 (en) 2008-03-03 2015-05-27 Novartis AG Compounds and compositions as tlr activity modulators
CA2720039A1 (en) * 2008-03-31 2009-10-08 Otsuka Pharmaceutical Co., Ltd. Method for detection of pneumococcus
JP2011516597A (ja) * 2008-04-16 2011-05-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
TWI551295B (zh) * 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
MX2011000823A (es) 2008-07-21 2011-04-11 Brigham & Womens Hospital Metodos y composiciones que se relacionan con oligosacaridos sinteticos de beta-1,6 glucosamina.
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US8318180B2 (en) * 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
SI3281947T1 (sl) 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
US9125951B2 (en) 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2012122533A2 (en) * 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
ES2626416T3 (es) 2009-10-30 2017-07-25 Glaxosmithkline Biologicals Sa Purificación de sacáridos capsulares de Staphilococcus aureus de tipo 5 y de tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US20130052204A1 (en) * 2009-11-16 2013-02-28 Clifford M. Snapper (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine
SG181712A1 (en) 2009-12-15 2012-07-30 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
BR122022002084B1 (pt) 2009-12-17 2022-08-16 Fina Biosolutions, Llc Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
AU2010351576B2 (en) 2010-04-23 2014-08-14 FinaBioSolutions, LLC Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
CN102268444B (zh) * 2010-06-03 2015-05-13 中国人民解放军军事医学科学院生物工程研究所 金黄色葡萄球菌截短SasA蛋白在大肠杆菌中的表达及应用
US8821894B2 (en) 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012009247A1 (en) * 2010-07-15 2012-01-19 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus protein sa2412
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
EP2638058B1 (en) * 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
SI3150222T1 (sl) * 2010-12-22 2020-02-28 Wyeth Llc Stabilni imunogenski sestavki antigenov staphylococcus aureus
US9109036B2 (en) * 2011-02-08 2015-08-18 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
HUE040734T2 (hu) * 2011-02-08 2019-03-28 Medimmune Llc Antitestek, amelyek specifikusan kötik staphylococcus aureus alfatoxinját és alkalmazási eljárások
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
KR102050267B1 (ko) 2011-06-19 2019-11-29 뉴욕 유니버시티 황색포도상구균 감염 및 연관된 질환을 치료하고 예방하는 방법
CN103764228B (zh) 2011-06-19 2017-09-08 纽约大学 作为新的抗炎剂和杀菌剂的白细胞毒素e/d
EP2744517B1 (en) 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
EP2773370A4 (en) 2011-10-31 2016-09-28 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2451
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
BR112014026861A2 (pt) 2012-04-26 2018-05-15 Univ Chicago antígenos de estafilococos coagulase e métodos de seu uso
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
KR20200023521A (ko) * 2012-05-09 2020-03-04 콘트라펙트 코포레이션 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
WO2013184900A2 (en) * 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
CN102898511B (zh) * 2012-10-19 2014-05-07 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌重组基因工程疫苗候选抗原i12c制备中的纯化方法
CN103087198B (zh) * 2013-01-21 2014-03-12 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原i1c及制备方法和应用
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
CN103333254A (zh) * 2013-06-21 2013-10-02 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）重组蛋白疫苗i1c的纯化方法
BR112016013514B1 (pt) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
CN105483138B (zh) * 2016-01-22 2019-03-26 吉林大学 一种与致病力相关的灰霉病菌基因BcAtm1及其应用
JP7117244B2 (ja) * 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
IL276608B2 (en) 2018-02-12 2024-04-01 Inimmune Corp Toll-like receptor ligands
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN109395072B (zh) * 2018-10-30 2021-11-30 中国兽医药品监察所 一种腐败梭菌α毒素基因工程疫苗及其生产方法
CN110055276A (zh) * 2019-01-28 2019-07-26 杨凌职业技术学院 一种金葡菌靶向抗菌肽细菌诱导型表达载体及其重组细胞
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CN110892989B (zh) * 2019-06-27 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解便秘功能的副干酪乳杆菌et-22
CN112391304B (zh) * 2019-08-15 2023-04-07 上海交通大学 副血链球菌f278及其用途
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN110590910A (zh) * 2019-09-27 2019-12-20 黑龙江八一农垦大学 能够增强细胞免疫应答和抗感染作用的合成肽
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
KR20220133262A (ko) * 2020-01-29 2022-10-04 더 잭슨 래보라토리 박테리아 혼합물
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB116556A (en) 1917-06-21 1918-06-20 British Thomson Houston Co Ltd Improvements in and relating to Dynamo Electric Machines.
SE335780B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1964-09-14 1971-06-07 Canadian Patents Dev
FR2227861B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1973-05-04 1976-07-02 Anvar
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69031951T2 (de) 1989-11-16 1998-08-13 Cornell Res Foundation Inc Transformation von tierischen Hautzellen mit hilfe von Partikeln
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
EP0648271B1 (en) 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
EP0648127B1 (en) * 1991-11-22 2003-04-16 Univax Biologics Incorporated Type i surface antigens associated with staphylococcus epidermidis
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US5750110A (en) 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
NZ261149A (en) 1993-02-05 1997-07-27 Smithkline Beecham Plc Staphylococcus aureus polypeptides and monoclonal antibodies therefrom, their production and use
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
RU2134295C1 (ru) 1994-01-21 1999-08-10 Паудерджект Вэксинс, Инк. Инструмент для подачи генетического материала, гильза для использования в приводимом в действие газом инструменте для подачи генетического материала (варианты) и способ подачи генетического материала
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9521146D0 (en) 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
RU2122862C1 (ru) * 1995-12-08 1998-12-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
ATE309271T1 (de) 1996-05-16 2005-11-15 Texas A & M Univ Sys Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
DK0914178T3 (da) 1996-06-18 2003-04-22 Alza Corp Anordning til forøgelse af transdermal afgivelse eller prøveudtagning af et middel
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CN1133472C (zh) 1996-12-20 2004-01-07 阿尔萨公司 增加经皮样剂流量的装置
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
IL136488A0 (en) 1997-12-02 2001-06-14 Powderject Vaccines Inc Transdermal delivery of particulate vaccine compositions
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
WO2000002522A2 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
DE69938784D1 (de) * 1998-07-15 2008-07-03 Brigham & Womens Hospital Polysaccharid-impfstoff gegen staphylokokken infektionen
JP2002523474A (ja) 1998-08-31 2002-07-30 インヒビテツクス，インコーポレイテツド ドナーの選択およびドナーの刺激によるブドウ球菌の免疫療法
EP2330192A1 (en) 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
AU771426B2 (en) * 1998-08-31 2004-03-18 Inhibitex, Inc. Multicomponent vaccines
WO2000015238A1 (en) 1998-09-14 2000-03-23 Nabi COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
WO2001034809A2 (en) 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AU2001288961A1 (en) * 2000-09-12 2002-06-18 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1423701B1 (en) * 2001-06-15 2012-07-25 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
JP2005532415A (ja) 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
US20040006209A1 (en) 2002-03-05 2004-01-08 Patti Joseph M. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
EP1583517B1 (en) 2002-11-12 2019-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
PL229487B1 (pl) * 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
RU2402347C2 (ru) 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
JP2011516597A (ja) * 2008-04-16 2011-05-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SI3150222T1 (sl) 2010-12-22 2020-02-28 Wyeth Llc Stabilni imunogenski sestavki antigenov staphylococcus aureus

Also Published As

Publication number Publication date
KR101505496B1 (ko) 2015-03-25
EP2305294B1 (en) 2015-04-01
ES2730275T3 (es) 2019-11-11
KR101359930B1 (ko) 2014-02-12
AU2005287502A1 (en) 2006-03-30
EP2305296A1 (en) 2011-04-06
EP2893938B1 (en) 2019-03-06
ES2472441T3 (es) 2014-07-01
NZ553776A (en) 2010-05-28
ES2540770T3 (es) 2015-07-13
MX2007003402A (es) 2007-05-10
JP5775005B2 (ja) 2015-09-09
IL181825A0 (en) 2007-07-04
IL223141A0 (en) 2012-12-31
JP2008513409A (ja) 2008-05-01
KR101508563B1 (ko) 2015-04-07
US20190076516A1 (en) 2019-03-14
CN101128215B (zh) 2012-10-10
MA28995B1 (fr) 2007-11-01
WO2006032475A2 (en) 2006-03-30
EP1804833A2 (en) 2007-07-11
KR20070058631A (ko) 2007-06-08
EP2893938A1 (en) 2015-07-15
IL181920A0 (en) 2011-07-31
NZ553775A (en) 2010-05-28
AU2005287532A1 (en) 2006-03-30
NO20071609L (no) 2007-06-18
JP2008513406A (ja) 2008-05-01
BRPI0515516A (pt) 2008-07-29
IL182639A0 (en) 2011-08-01
WO2006032500A2 (en) 2006-03-30
JP2015166365A (ja) 2015-09-24
EP2305295A1 (en) 2011-04-06
EP2298340B1 (en) 2014-04-16
CN101128215A (zh) 2008-02-20
MA28994B1 (fr) 2007-11-01
CA2983954A1 (en) 2006-03-30
ES2540771T3 (es) 2015-07-13
EP2181714A3 (en) 2010-06-23
NO20071610L (no) 2007-06-20
BRPI0515520A (pt) 2008-07-29
JP2018048132A (ja) 2018-03-29
EP2305295B1 (en) 2015-04-01
BR122016029840B1 (pt) 2021-10-13
WO2006032500A3 (en) 2006-06-22
KR20070054732A (ko) 2007-05-29
WO2006032472A2 (en) 2006-03-30
US20200179504A1 (en) 2020-06-11
RU2402347C2 (ru) 2010-10-27
MX2007003400A (es) 2008-03-04
NZ582441A (en) 2011-09-30
AU2005287532B2 (en) 2011-09-01
EP2181714A2 (en) 2010-05-05
WO2006032475A3 (en) 2007-01-25
US20150328302A1 (en) 2015-11-19
US20080085289A1 (en) 2008-04-10
EP2305294A1 (en) 2011-04-06
KR20120128724A (ko) 2012-11-27
US20080095777A1 (en) 2008-04-24
ZA200702224B (en) 2016-09-28
CA2580103C (en) 2021-11-16
RU2007110029A (ru) 2008-10-27
AU2005287505A1 (en) 2006-03-30
CN102657855B (zh) 2015-12-09
JP6594385B2 (ja) 2019-10-23
US20110008385A1 (en) 2011-01-13
EP2298340A1 (en) 2011-03-23
WO2006032472A3 (en) 2006-07-20
EP1791559A2 (en) 2007-06-06
CA2584290A1 (en) 2006-03-30
BRPI0515516B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25
US10548963B2 (en) 2020-02-04
CA2580103A1 (en) 2006-03-30
AU2005287502B2 (en) 2011-12-01
NZ593693A (en) 2013-08-30
CA2580137A1 (en) 2006-03-30
EP1793849A2 (en) 2007-06-13
IL223141B (en) 2018-06-28
CA2983954C (en) 2019-09-17
JP2012107028A (ja) 2012-06-07
CN102657855A (zh) 2012-09-12
IL181920A (en) 2014-12-31
HK1155658A1 (en) 2012-05-25
KR20130087633A (ko) 2013-08-06

Similar Documents

Publication Publication Date Title
US10548963B2 (en) Immunogenic composition for use in vaccination against staphylococci
RU2521501C2 (ru) Иммуногенная композиция для применения в вакцинации против стафилококков
AU2011203550B2 (en) Immunogenic composition
HK1139869A (en) Immunogenic composition for use in vaccination against staphylococcei
HK1155658B (en) Immunogenic composition for use in vaccination against staphylococcei
HK1175704A (en) Immunogenic composition for use in vaccination against staphylococcei

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.